98%
921
2 minutes
20
Pathogenic germline variants (PGVs) may be under-detected as causative etiologies in patients with non-small cell lung cancer (NSCLC). The prevalence of PGVs has been reported between 1 and 15% of patients, depending on the patient population. The rate within Hispanic/Latinx populations remains unknown. We retrospectively analyzed the genomic results (Guardant360, Redwood City, CA, USA) of 878 patients with advanced or metastatic NSCLC at five centers in South Florida, USA, from 2019 to 2022 to analyze the rate of incidental PGVs (iPGVs) identified via circulating cell-free tumor DNA (ctDNA). We then stratified the results by tumor histology, age, gender, race, ethnicity, genetic pathway, and co-mutations. Twenty-one iPGVs were identified (21/878 = 2.4%). Among the 21 iPGVs identified, 14 patients were female (66.7%) and 7 were male (33.3%), with a median age of 67 years and tobacco history of 2.5 pack-years. In total, 52.4% of patients identified as Hispanic/Latinx ( = 11) of any race; 19.0% as Ashkenazi Jewish ( = 4), 9.5% as non-Hispanic/Latinx black ( = 2), and 19.0% as non-Hispanic/Latinx white ( = 4). iPGVs in the homologous recombination repair pathway were solely expressed in this cohort (10 , 8 , and 3 ). In total, 76% (16/21) of patients with iPGVs co-expressed somatic alterations, with 56% (9/16) demonstrating alterations in targetable genes. Overall, our real-world findings offer a point prevalence of iPGVs in patients with NSCLC of diverse populations, such as patients who report Hispanic/Latinx ethnicity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10968784 | PMC |
http://dx.doi.org/10.3390/cancers16061150 | DOI Listing |
Clin Lung Cancer
August 2025
Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL; Tempus AI, Tempus, Chicago, IL.
Introduction: Several studies have sought to determine the prevalence of BRCA1/BRCA2 in patient populations, but few have studied impacts of such alterations on patient outcomes beyond breast, ovarian, prostate and pancreatic cancers. This study assessed patient outcomes from a large real-world evidence (RWE) database for patients with EGFR-mutated advanced non-small-cell lung cancer (aNSCLC) who also had incidental pathogenic germline variants (iPGVs) in BRCA1, BRCA2 or PALB2 identified by a well-validated liquid biopsy.
Materials And Methods: Outcomes from patients included in GuardantINFORM, a RWE database, from Oct 2018-June 2024 with a diagnosis of aNSCLC and an incidental pathogenic germline variant (iPGV) in BRCA1/2 or PALB2 included in OncoKB treated with EGFR monotherapy (gBRCA/PALB2+) were matched in 1:5 using coarsened exact matching to a control cohort without iPGVs (control).
Cancers (Basel)
March 2024
University of Miami Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, Miami, FL 33136, USA.